Pulmatrix, Inc. reported second quarter 2026 financial results and provided a corporate update regarding its proposed merger with Eos SENOLYTIX. The company filed a Form S-4 related to the merger agreement announced in March 2026, which is anticipated to close in the third quarter of 2026. For the three months ended June 30, 2026, research and development expenses were less than $0.1 million, while general and administrative expenses decreased approximately $0.5 million to $1.0 million compared to the prior year period. The company reported a net loss attributable to common stockholders of $1.052 million, or $0.29 per share, and held $2.2 million in cash and cash equivalents as of June 30, 2026. Pulmatrix is a biopharmaceutical company focused on developing novel inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ technology.